Printer Friendly

INTERPHARM LABORATORIES REPORTS AN INCREASE IN SALES AND NET INCOME IN 1991

 INTERPHARM LABORATORIES REPORTS AN INCREASE IN SALES
 AND NET INCOME IN 1991
 NESS-ZIONA, Israel, March 31 /PRNewswire/ -- InterPharm Laboratories Ltd. today reported sales of $35.2 million for the year ending Dec. 31, 1991, an increase of 40 percent compared with $25.2 million in 1990. Net income totalled $4.3 million or 68 cents per share in 1991, an increase of 24 percent compared to $3.5 million or 55 cents per share in 1990.
 "Our sales can be directly attributed to increased sales of Frone(R), our native beta-interferon. This increase was mainly due to a new indication of Frone as an adjuvant therapy for breast and uterine cancers and increased marketing efforts by Ares-Serono," said Dr. Yoram Karmon, president and chief executive officer of the company.
 Gross R&D spending totalled $6.2 million in 1991, a 27 percent increase over the prior year. This reflects R&D for recombinant beta- interferon (RBIF), which is virtually identical to the natural beta- interferon produced by the human body, and research efforts for Interleukin-6 (IL-6), an immune system stimulator, which is showing promise in the treatment of severe side effects associated with cancer therapy.
 Capital investments in 1991 amounted to $8.4 million primarily for the expansion of production facilities for Frone and construction of a RBIF manufacturing site and R&D laboratories.
 InterPharm Laboratories Ltd. is a member of The Ares-Serono Group, a worldwide developer and marketer of pharmaceutical and diagnostic products, with executive headquarters in Geneva, Switzerland and operating headquarters in Boston, Mass. The group operates subsidiaries and manufacturing facilities in more than 20 countries.
 InterPharm Laboratories Ltd.'s shares are traded over-the-counter in the United States.
 INTERPHARM LABORATORIES LTD.
 Financial Summary
 Year Ending Dec. 31
 1991 1990
 Net sales $35,196,070 $25,205,390
 Net income 4,274,795 3,458,481
 Earnings per share 68 cents 55 cents
 Weighted average number
 of shares outstanding 6,240,700 6,237,385
 -0- 3/31/92
 /CONTACT: Gina Cella of Ares-Serono, 617-982-9000 ext. 251/ CO: The Ares-Serono Group; InterPharm Laboratories Ltd. ST: Massachusetts IN: MTC SU: ERN


EG -- NE014 -- 3577 03/31/92 16:36 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 31, 1992
Words:360
Previous Article:PEP BOYS ADDS DIRECTOR, INCREASES DIVIDEND
Next Article:WHEELING-PITTSBURGH STEEL ANNOUNCES APPOINTMENTS
Topics:


Related Articles
INTERPHARM LABORATORIES REPORTS 1991 THIRD QUARTER AND NINE MONTHS SALES AND EARNINGS
INTERPHARM LABORATORIES LTD. REPORTS EARNINGS AND INCOME FOR THE SECOND QUARTER OF 1992
INTERPHARM LABORATORIES LTD. REPORTS THIRD QUARTER AND NINE MONTHS EARNINGS AND INCOME
INTERPHARM LABORATORIES LTD. REPORTS 1993 FIRST QUARTER RESULTS
INTERPHARM LABORATORIES LTD. REPORTS REVENUES AND NET INCOME FOR THE SECOND QUARTER OF 1993
INTERPHARM LABORATORIES LTD. REPORTS REVENUES AND INCOME FOR THE THIRD QUARTER OF 1993
INTERPHARM LABORATORIES LTD. REPORTS 1993 RESULTS OF OPERATIONS
INTERPHARM LABORATORIES LIMITED REPORTS 1994 FIRST QUARTER RESULTS
INTERPHARM LABORATORIES LIMITED REPORTS 1994 SECOND QUARTER RESULTS
INTERPHARM LABORATORIES LTD. REPORTS 1994 THIRD QUARTER RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters